ADAP Adaptimmune Therapeutics plc

5.68
+0  (5%)
Previous Close 5.41
Open 5.50
Price To book 2.31
Market Cap 402.12M
Shares 70,795,000
Volume 414,820
Short Ratio 1.53
Av. Daily Volume 239,850

SEC filingsSee all SEC filings

  1. CT ORDER - Confidential treatment order 17771894
  2. PRE 14A - Other preliminary proxy statements 17756867
  3. 8-K - Current report 17753993
  4. 10-Q/A (Amend) - Quarterly report (Sections 13 or 15(d)) 17746469
  5. 8-K - Current report 17741235

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 to be initiated 2H 2017.
NY-ESO T-cell therapy
Synovial sarcoma - cancer
Further trials planned for 2H 2016
NY-ESO T-cell therapy
Ovarian cancer
Pivotal trial placed on clinical hold due to non-safety issues. Hold released November 2016. Envisage initiation 4Q 2016 or 1Q 2017
NY-ESO T-cell therapy
Myxoid round cell liposarcoma (MRCLS)
Further trials planned for 1H 2017.
NY-ESO T-cell therapy
Myeloma
Phase 1/2 initiated November 2015. Data are due 2017.
NY-ESO T-cell therapy
Non-small cell lung cancer (NSCLC)

SEC Filings

  1. CT ORDER - Confidential treatment order 17771894
  2. PRE 14A - Other preliminary proxy statements 17756867
  3. 8-K - Current report 17753993
  4. 10-Q/A (Amend) - Quarterly report (Sections 13 or 15(d)) 17746469
  5. 8-K - Current report 17741235
  6. 424B5 - Prospectus (Rule 424(b)(5)) 17741218
  7. 8-K - Current report 17724643
  8. 8-K - Current report 17707552
  9. 424B5 - Prospectus (Rule 424(b)(5)) 17707521
  10. 424B5 - Prospectus (Rule 424(b)(5)) 17704985